John Weisnagel Selected Research

pegvisomant

3/2012

Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John Weisnagel Research Topics

Disease

2	Insulin Resistance 11/2018 - 06/2015
2	Obesity 11/2018 - 06/2010
1	Type 2 Diabetes Mellitus (MODY) 06/2015
1	Acromegaly 03/2012

Drug/Important Bio-Agent (IBA)

2	Glucose (Dextrose)FDA LinkGeneric 11/2018 - 06/2015
1	LeptinIBA 11/2018
1	Insulin (Novolin)FDA Link 11/2018
1	AdiponectinIBA 11/2018
1	hydroxide ionIBA 06/2015
1	25-hydroxyvitamin DIBA 06/2015
1	C-PeptideIBA 06/2015
1	Vitamin D FDA LinkGeneric 06/2015
1	Biomarkers (Surrogate Marker)IBA 06/2015
1	Temozolomide (Temodar)FDA LinkGeneric 03/2012
1	Octreotide (Sandostatin)FDA LinkGeneric 03/2012
1	pegvisomant FDA LinkGeneric 03/2012
1	Insulin-Like Growth Factor I (IGF-1)IBA 03/2012
1	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 06/2010

Therapy/Procedure

1	Radiotherapy 03/2012
1	Therapeutics 03/2012